Genomics England-supported study reveals new opportunities for personalised TB treatment
A new study led by the University of Oxford-based CRyPTIC consortium, working with Genomics England, Public Health England and the NIHR, reveals new opportunities for personalised medicine in the treatment of tuberculosis (TB).
The study, ‘Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing’, demonstrates much greater accuracy in predicting the susceptibility of the bacterium to anti-TB drugs than had been expected. This more detailed understanding of TB’s genetic code now allows researchers to predict which commonly used anti-TB drugs are best for treating a patient’s infection and which are not.
Genomics England Chief Scientist, Professor Mark Caulfield, said:
Lead investigator, Dr Tim Walker, Academic Clinical Lecturer in Microbiology and Infectious Diseases at the University of Oxford’s Nuffield Department of Medicine, said:
The paper was published on 26 September in the New England Journal of Medicine, with its findings announced at the United Nations General Assembly high-level meeting on tuberculosis.